Work

Pilot Clinical Trial of Lymphocyte-Selective Pentostatin Plus Cyclophosphamide Conditioning, High Dose Sirolimus and Pre-Emptive DLI with Rapamycin-Resistant Donor CD4+ T Cells

Year: 2015

Type: article

Abstract: We recently found that early pre-emptiveDLI with donor CD4+ T-Cells cultured in rapamycin (T-Rapa) allowed allo-engraftment after low-intensity fludarabine plus cyclophosphamide (Cy) host conditioning (Blood, 2013). To evaluate further reductions in conditioning intensity, we conducted a pilot clinical trial of allogeneic HSCT using a novel regimen of pentostatin and low-dose, daily cyclophosphamide (PC) in patients with refractory renal cell carcinoma (RCC, n=10; Table 1). After PC conditioning, patients received high dose sirolimus, a T-replete matched related donor PBSC graft, and multiple, pre-emptive DLI using T-Rapa cells (schema, Fig.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.11.455